MD Anderson studies skin cancer patients resistant to leading therapy

Researchers at The University of Texas MD Anderson Cancer Center may have found a way to more accurately predict which patients will likely respond to genomic-based follow-up therapies, by looking at unique “protein patterns” in melanoma patients. “There are patients whose DNA does not reveal how their melanomas became resistant to BRAF inhibitors,” said Lawrence Kwong, Ph.D., instructor in Genomic Medicine at MD Anderson. “So we looked at patterns of changes in 150 proteins which can give clues to the causes of resistance, even when DNA sequencing data is uninformative.” Read more here.